-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng received the CDE acceptance for the marketing application of Brainshang Lesheng Granules submitted in the new drug category 1.
1.
This is the first class 1 new cerebrovascular Chinese patent medicine reported for production in China
.
Public information shows that Naoshang Lesheng Granule is a new Chinese medicine developed by Henan Tianfang Pharmaceutical and Shenzhen Shasong Lesheng.
After craniocerebral surgery, the symptoms such as weakness of Qi and blood, damage to the brain and veins, stasis and meridian paralysis
.
It is understood that the current market size of proprietary Chinese medicines in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) is more than 200 billion yuan.
Disease medication has always been two important therapeutic areas
.
Among them, the market size of Chinese patent medicines for cerebrovascular diseases in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 40 billion yuan in 2020
.
The industry predicts that in the future, as this Chinese patent medicine is successfully approved for listing, its market development space will be considerable
.
It is worth noting that in fact, in addition to the recent CDE approval of the marketing application of Naoshang Lesheng Granules, many companies have also submitted clinical and marketing applications for Class 1 new medicines of proprietary Chinese medicines
.
For example, on October 9, Kangyuan Pharmaceutical submitted a clinical application for the new drug of Jiuwei Shufeng Pingchuan Granules, which became the 37th class 1 new drug declared for Chinese patent medicine this year
.
The industry believes that, as a whole, as domestic pharmaceutical companies continue to improve their R&D capabilities, the era of innovative Chinese medicines has come
.
In fact, some data show that in recent years, the declaration of Class 1 new medicines of proprietary Chinese medicines is showing a surge
.
In 2018, there were 2 product declarations for clinical application, and the number of declarations for 2019 was 0.
In 2020, 5 products were declared for marketing and 9 products were declared for clinical application.
Since 2021, 7 products have been declared for marketing and 30 products have been declared for clinical application.
.
.
In terms of the new medicines approved and declared in the past few years, proprietary Chinese medicine companies such as Tasly, Yiling Pharmaceutical, and Kangyuan Pharmaceutical have spared no effort in the development of new medicines, and have made breakthroughs in their product lines from the perspective of the company itself.
.
In addition, some chemical drug giants are no longer stingy, and are investing heavily in the research and development of new Chinese patent medicines
.
For example, Renfu, the leading drug company for anesthesia and sedation, the company's first class 1 new Chinese patent medicine, Guangxiancao total flavonoids capsules, has already been declared for listing
.
With the continuous efforts of these companies, the industry expects that when the products enter the harvest period, the company will continue to grow its competitiveness in the market, and it will also further promote the accelerated development of the Chinese medicine industry
.
Generally speaking, in the past, China's traditional Chinese medicine market has long faced problems such as large and scattered production enterprises, serious product homogeneity, and lack of core competitiveness.
The industry urgently needs to adjust and upgrade
.
However, with the continuous implementation of a series of medical reform policies in recent years, the entire Chinese medicine industry has begun to continuously upgrade, and the speed of innovation has also begun to accelerate
.
The industry believes that, in this context, domestic pharmaceutical companies should seize the opportunity to increase the layout of new class 1 Chinese medicines
.
However, it should be noted that the development and research of new Chinese medicines is a huge systematic project, which requires the overall collaboration of multiple professions and departments, as well as the mutual penetration and integration of multiple disciplines.
Therefore, relevant pharmaceutical companies also need to continuously absorb modern scientific concepts.
, Using modern science and technology and methods to develop modern new Chinese medicines to better meet people's needs
.
1.
This is the first class 1 new cerebrovascular Chinese patent medicine reported for production in China
.
Public information shows that Naoshang Lesheng Granule is a new Chinese medicine developed by Henan Tianfang Pharmaceutical and Shenzhen Shasong Lesheng.
After craniocerebral surgery, the symptoms such as weakness of Qi and blood, damage to the brain and veins, stasis and meridian paralysis
.
It is understood that the current market size of proprietary Chinese medicines in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) is more than 200 billion yuan.
Disease medication has always been two important therapeutic areas
.
Among them, the market size of Chinese patent medicines for cerebrovascular diseases in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 40 billion yuan in 2020
.
The industry predicts that in the future, as this Chinese patent medicine is successfully approved for listing, its market development space will be considerable
.
It is worth noting that in fact, in addition to the recent CDE approval of the marketing application of Naoshang Lesheng Granules, many companies have also submitted clinical and marketing applications for Class 1 new medicines of proprietary Chinese medicines
.
For example, on October 9, Kangyuan Pharmaceutical submitted a clinical application for the new drug of Jiuwei Shufeng Pingchuan Granules, which became the 37th class 1 new drug declared for Chinese patent medicine this year
.
The industry believes that, as a whole, as domestic pharmaceutical companies continue to improve their R&D capabilities, the era of innovative Chinese medicines has come
.
In fact, some data show that in recent years, the declaration of Class 1 new medicines of proprietary Chinese medicines is showing a surge
.
In 2018, there were 2 product declarations for clinical application, and the number of declarations for 2019 was 0.
In 2020, 5 products were declared for marketing and 9 products were declared for clinical application.
Since 2021, 7 products have been declared for marketing and 30 products have been declared for clinical application.
.
.
In terms of the new medicines approved and declared in the past few years, proprietary Chinese medicine companies such as Tasly, Yiling Pharmaceutical, and Kangyuan Pharmaceutical have spared no effort in the development of new medicines, and have made breakthroughs in their product lines from the perspective of the company itself.
.
In addition, some chemical drug giants are no longer stingy, and are investing heavily in the research and development of new Chinese patent medicines
.
For example, Renfu, the leading drug company for anesthesia and sedation, the company's first class 1 new Chinese patent medicine, Guangxiancao total flavonoids capsules, has already been declared for listing
.
With the continuous efforts of these companies, the industry expects that when the products enter the harvest period, the company will continue to grow its competitiveness in the market, and it will also further promote the accelerated development of the Chinese medicine industry
.
Generally speaking, in the past, China's traditional Chinese medicine market has long faced problems such as large and scattered production enterprises, serious product homogeneity, and lack of core competitiveness.
The industry urgently needs to adjust and upgrade
.
However, with the continuous implementation of a series of medical reform policies in recent years, the entire Chinese medicine industry has begun to continuously upgrade, and the speed of innovation has also begun to accelerate
.
The industry believes that, in this context, domestic pharmaceutical companies should seize the opportunity to increase the layout of new class 1 Chinese medicines
.
However, it should be noted that the development and research of new Chinese medicines is a huge systematic project, which requires the overall collaboration of multiple professions and departments, as well as the mutual penetration and integration of multiple disciplines.
Therefore, relevant pharmaceutical companies also need to continuously absorb modern scientific concepts.
, Using modern science and technology and methods to develop modern new Chinese medicines to better meet people's needs
.
